- Home
- Publications
- Publication Search
- Publication Details
Title
STAT3: Versatile Functions in Non-Small Cell Lung Cancer
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 5, Pages 1107
Publisher
MDPI AG
Online
2020-04-30
DOI
10.3390/cancers12051107
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Inflammatory regulatory network mediated by the joint action of NF-kB, STAT3, and AP-1 factors is involved in many human cancers
- (2019) Zhe Ji et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
- (2019) Deborah B Doroshow et al. CLINICAL CANCER RESEARCH
- A Phase Ib Study of the Combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs
- (2019) Ji Soo Park et al. LUNG CANCER
- JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression
- (2019) Julian Mohrherr et al. INTERNATIONAL JOURNAL OF CANCER
- Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
- (2019) Fan Luo et al. Journal for ImmunoTherapy of Cancer
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
- (2019) Longchuan Bai et al. CANCER CELL
- Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
- (2019) Haibin Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
- (2018) D Westover et al. ANNALS OF ONCOLOGY
- Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis
- (2018) Bin Zou et al. BMC BIOINFORMATICS
- The role of STAT3 in leading the crosstalk between human cancers and the immune system
- (2018) Yu Wang et al. CANCER LETTERS
- STAT3 isoforms: Alternative fates in cancer?
- (2018) Petra Aigner et al. CYTOKINE
- Interleukin-10 Directly Inhibits CD8 + T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity
- (2018) Logan K. Smith et al. IMMUNITY
- KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
- (2018) Marta Román et al. Molecular Cancer
- Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition
- (2018) Emanuele Giurisato et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting VEGF/VEGFR to Modulate Antitumor Immunity
- (2018) Ju Yang et al. Frontiers in Immunology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Abstract 2938: In vivo assessment of the combination of the JAK1 selective inhibitor itacitinib with first- and second-generation EGFR inhibitors in models of non-small cell lung cancer
- (2018) Matthew C. Stubbs et al. CANCER RESEARCH
- Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog - Mutated Non–Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure
- (2018) David A. Barbie et al. Clinical Lung Cancer
- STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis
- (2018) Stephen D'Amico et al. GENES & DEVELOPMENT
- Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer
- (2018) Mauricio S. Caetano et al. Nature Communications
- Do STAT3 inhibitors have potential in the future for cancer therapy?
- (2017) Andrea L.A. Wong et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer
- (2017) Xiaohui Zhang et al. International Journal of Clinical Oncology
- A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR -Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib
- (2017) Helena A. Yu et al. Journal of Thoracic Oncology
- Lung cancer: current therapies and new targeted treatments
- (2017) Fred R Hirsch et al. LANCET
- A growth hormone receptor SNP promotes lung cancer by impairment of SOCS2-mediated degradation
- (2017) Y Chhabra et al. ONCOGENE
- JAK2 variations and functions in lung adenocarcinoma
- (2017) Yanjun Xu et al. TUMOR BIOLOGY
- Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation
- (2017) Jingjiao Zhou et al. Cancer Immunology Research
- JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
- (2017) Chunwan Lu et al. OncoImmunology
- Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized, double-blind safety and efficacy trial.
- (2017) J. R. Rigas et al. JOURNAL OF CLINICAL ONCOLOGY
- ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial.
- (2017) M. Schuster et al. JOURNAL OF CLINICAL ONCOLOGY
- The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
- (2016) Nan Zhang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Clinical Implications of Genomic Discoveries in Lung Cancer
- (2016) Charles Swanton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models
- (2016) Alessia Bottos et al. Nature Communications
- JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
- (2015) Kathrin Schönberg et al. CANCER RESEARCH
- Interleukin-6 Prevents the Initiation but Enhances the Progression of Lung Cancer
- (2015) Z. Qu et al. CANCER RESEARCH
- AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
- (2015) David Hong et al. Science Translational Medicine
- Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis
- (2015) Beatrice Grabner et al. Nature Communications
- STAT3 regulated ARF expression suppresses prostate cancer metastasis
- (2015) Jan Pencik et al. Nature Communications
- Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells
- (2015) Svetlana Karakhanova et al. OncoImmunology
- The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis
- (2015) Qing Chang et al. NEOPLASIA
- Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC
- (2014) Yuan Hu et al. APOPTOSIS
- Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance
- (2014) D. Gotthardt et al. BLOOD
- Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
- (2014) Ho-June Lee et al. CANCER CELL
- A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
- (2014) E. Angevin et al. CLINICAL CANCER RESEARCH
- CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells
- (2014) Andreas Herrmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer
- (2014) Lanxi Song et al. Journal of Thoracic Oncology
- Differential roles of STAT3 in the initiation and growth of lung cancer
- (2014) J Zhou et al. ONCOGENE
- VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2
- (2014) D Zhao et al. ONCOGENE
- Targeting pathways downstream of KRAS in lung adenocarcinoma
- (2014) Zehua Zhu et al. PHARMACOGENOMICS
- The two faces of IL-6 in the tumor microenvironment
- (2014) Daniel T. Fisher et al. SEMINARS IN IMMUNOLOGY
- Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit
- (2014) Z. Zhu et al. Cancer Discovery
- STAT3 in Cancer—Friend or Foe?
- (2014) Hai-Feng Zhang et al. Cancers
- The Role of STAT3 in Non-Small Cell Lung Cancer
- (2014) Daijiro Harada et al. Cancers
- Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma
- (2013) C Gordziel et al. BRITISH JOURNAL OF CANCER
- Epidemiology of Lung Cancer
- (2013) Anthony J. Alberg et al. CHEST
- A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer
- (2013) Y.H. Xu et al. EJSO
- Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model
- (2013) Toshi Murakami et al. LUNG CANCER
- AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors
- (2013) E. R. Plimack et al. ONCOLOGIST
- NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer
- (2013) Yihui Fan et al. Protein & Cell
- Inhibitory Roles of Signal Transducer and Activator of Transcription 3 in Antitumor Immunity during Carcinogen-Induced Lung Tumorigenesis
- (2012) S. Ihara et al. CANCER RESEARCH
- Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
- (2012) Marcin Imielinski et al. CELL
- Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis
- (2012) Amir Sonnenblick et al. Clinical & Translational Oncology
- Signal Transducer and Activator of Transcription 3 (STAT3) Protein Suppresses Adenoma-to-carcinoma Transition inApcmin/+Mice via Regulation of Snail-1 (SNAI) Protein Stability
- (2012) Jongdae Lee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Correlation of Activated STAT3 Expression with Clinicopathologic Features in Lung Adenocarcinoma and Squamous Cell Carcinoma
- (2012) Richeng Jiang et al. Molecular Diagnosis & Therapy
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma
- (2012) Brendan D. Looyenga et al. PLoS One
- STAT3 negatively regulates thyroid tumorigenesis
- (2012) J. P. Couto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer
- (2011) Trevor J Bayliss et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- p19ARF/p14ARF controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma
- (2011) Doris Schneller et al. HEPATOLOGY
- Down-regulation of JAK1 by RNA interference inhibits growth of the lung cancer cell line A549 and interferes with the PI3K/mTOR pathway
- (2011) Dan Liu et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer
- (2011) Mei Zhao et al. LUNG CANCER
- Tobacco Smoke Promotes Lung Tumorigenesis by Triggering IKKβ- and JNK1-Dependent Inflammation
- (2010) Hiroyuki Takahashi et al. CANCER CELL
- Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment
- (2009) Marcin Kortylewski et al. CANCER CELL
- The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
- (2009) Michael Hedvat et al. CANCER CELL
- IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer
- (2009) Sergei Grivennikov et al. CANCER CELL
- Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
- (2009) Sergei I. Grivennikov et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Stat3 Is a Negative Regulator of Intestinal Tumor Progression in ApcMin Mice
- (2009) Monica Musteanu et al. GASTROENTEROLOGY
- The Cooperative Induction of Hypoxia-Inducible Factor-1 and STAT3 during Hypoxia Induced an Impairment of Tumor Susceptibility to CTL-Mediated Cell Lysis
- (2009) M. Z. Noman et al. JOURNAL OF IMMUNOLOGY
- Immune surveillance: a balance between protumor and antitumor immunity
- (2008) Suzanne Ostrand-Rosenberg CURRENT OPINION IN GENETICS & DEVELOPMENT
- Role of Stat3 in suppressing anti-tumor immunity
- (2008) Marcin Kortylewski et al. CURRENT OPINION IN IMMUNOLOGY
- Protein tyrosine phosphatases in the JAK/STAT pathway
- (2008) Dan Xu Frontiers in Bioscience-Landmark
- Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway
- (2008) N. de la Iglesia et al. GENES & DEVELOPMENT
- Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice
- (2008) Maciej Kujawski et al. JOURNAL OF CLINICAL INVESTIGATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now